chronic lymphocytic leukaemia
Johnson & Johnson presents promising data on leukaemia treatment
June 16, 2025Medical Communications, Research and Development European Hematology Association, Janssen-Cilag, Johnson & Johnson, Oncology, chronic lymphocytic leukaemia, clinical trial
Janssen-Cilag, a Johnson & Johnson company, has announced results from a matching-adjusted indirect comparison presented at this year’s European Hematology …
AstraZeneca’s AMPLIFY trial interim analysis demonstrates positive results for Calquence plus venetoclax
July 30, 2024Research and Development AstraZeneca, Haematology, chronic lymphocytic leukaemia, haematology, trial analysis
AstraZeneca has announced positive high-level results from an interim analysis for its AMPLIFY phase 3 trial, combining AstraZeneca’s Calquence (acalabrutinib) …
Six-year follow-up data shows Imbruvica’s benefit in high-risk chronic lymphocytic leukaemia
December 7, 2020Research and Development, Sales and Marketing Janssen, chronic lymphocytic leukaemia, imbruvica
Janssen has revealed multiple pooled data analyses for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) in the first-line treatment …
Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia
December 9, 2019Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax
AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …
Janssen chalks up two more indications in Europe for Imbruvica combo therapies
August 14, 2019Research and Development, Sales and Marketing Europe, Janssen, chronic lymphocytic leukaemia, imbruvica, pharma
Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving …
AstraZeneca’s Calquence shows strength in most common adult leukaemia
June 6, 2019Research and Development AstraZeneca, Calquence, chronic lymphocytic leukaemia, pharma
AstraZeneca has unveiled new Phase 3 data for Calquence (acalabrutinib) in treatment-naïve chronic lymphocytic leukaemia, showing that the drug met …
Lowered price wins NICE approval for Janssen leukaemia treatment
November 25, 2016Medical Communications, Sales and Marketing Janssen, NICE, SMC, chronic lymphocytic leukaemia, ibrutinib, imbruvica
After being knocked back in the beginning of June this year, NICE has announced that Janssen’s Imbruvica (ibrutinib) will now …
Roche’s MabThera gets European approval to treat chronic lymphocytic leukaemia
May 31, 2016Manufacturing and Production Roche, chronic lymphocytic leukaemia, drug approval, regulation
Swiss drugmaker Roche (SIX: ROG) on Tuesday said the European Commission (EC) has approved the subcutaneous (SC) formulation of its …
Arzerra approved by US FDA for leukaemia
January 20, 2016Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application
The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …
AstraZeneca in $5bn Acerta buyout talks
December 14, 2015Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover
AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …
Abbvie and Roche report success in Phase II leukaemia trial
August 13, 2015Research and Development AbbVie, Breakthrough Therapy Designation, CLL, EMA, FDA, Roche, chronic lymphocytic leukaemia, leukaemia, venetoclax
AbbVie plans to submit regulatory applications for its leukaemia drug venetoclax to the FDA and the EMA before the end …
EMA approvals for rival blood cancer drugs
July 27, 2014Research and Development, Sales and Marketing CLL, Gilead, Janssen, chronic lymphocytic leukaemia, imbruvica, zydelig
Gilead and Janssen are set to face off in Europe after the CHMP recommended both of their rival blood cancer …
Biogen gets CHMP thumbs up
May 27, 2014Sales and Marketing Biogen, CHMP, Gazyvaro (obinutuzumab), Nuwiq, Octapharma, Orphan, Roche, chronic lymphocytic leukaemia, plegridy
Biogen Idec is celebrating after the Committee for Medicinal Products for Human Use (CHMP) gave its multiple sclerosis drug Plegridy …
Latest content
FibroFind appoints Lee Borthwick as CEO
